Stopping Statins After 75 Shows No Mortality Risk in First Randomized Trial

For decades, doctors have kept older patients on statins almost as a matter of course—a preventive measure that seemed to make sense, a chemical hedge against heart disease. But a question has lingered in the background of medical practice: what actually happens if you stop? A new randomized controlled trial offers the first rigorous answer for people over 75 at low cardiovascular risk, and the result is striking in its simplicity: nothing bad happens.

The study followed adults aged 75 and older who had been taking statins but carried a low risk of heart disease. Researchers divided them into two groups—one continued their medication, the other stopped it entirely. Over three years, survival rates were essentially identical between the two groups. No mortality advantage accrued to those who kept taking the pills. No hidden danger emerged for those who quit.

This matters because statins have become one of the most prescribed medications in the world, particularly among the elderly. They work by lowering cholesterol, and for people at genuine high risk of heart attack or stroke, the evidence supporting their use is solid. But the older you get, and the lower your actual cardiovascular risk, the more reasonable it becomes to ask whether the medication is still doing anything for you. Many patients in their late seventies and eighties are taking statins out of habit, or because no one has ever suggested stopping, or because the original prescription was written when their risk profile looked different.

The trial's findings suggest that at least for this population—older adults with low baseline risk—continuing statins may be unnecessary. That's a meaningful distinction. It opens a door to what doctors call deprescribing: the deliberate, evidence-based removal of medications that are no longer serving a clear purpose. For an elderly patient already juggling multiple pills, each with its own side effects and interactions, the ability to safely eliminate one is genuinely valuable.

But the study comes with an important caveat that experts have been quick to point out. The trial, while rigorous in design, was not large enough to detect smaller differences in mortality that might still exist. In statistical terms, it was underpowered. This means the study can confidently say that stopping statins didn't cause a dramatic increase in deaths, but it cannot rule out more modest effects that a larger trial might have caught. It's the difference between proving something is safe and proving something is completely harmless.

The implications for clinical practice are still significant, though. Guidelines for prescribing in the elderly have long erred on the side of caution, sometimes to the point of treating numbers rather than people. A patient with a cholesterol reading of 220 and no history of heart disease might receive a statin prescription that lasts for years, even decades, without anyone stopping to ask whether it's still appropriate. This trial suggests that conversation is overdue.

What comes next is likely a period of recalibration. Cardiologists and primary care doctors will need to weigh this evidence against existing guidelines and their own clinical experience. Some will move quickly to offer deprescribing conversations to eligible patients. Others will wait for larger, more definitive trials. The medical community's response will shape whether this finding becomes a genuine shift in how we treat the oldest patients, or remains a footnote in the literature—interesting but not quite enough to change practice.